Alar Pharmaceuticals Inc. (TPEX: 6785)
183.00
-8.00 (-4.19%)
Sep 10, 2024, 1:30 PM CST
Alar Pharmaceuticals Company Description
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan.
It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression.
Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Alar Pharmaceuticals Inc.
Country | Taiwan |
Founded | 2016 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 22 |
CEO | Yung-Shun Wen |
Contact Details
Address: No. 32, Keya Road Taichung Taiwan | |
Phone | 886 4 2463 7115 |
Website | alarpharm.com |
Stock Details
Ticker Symbol | 6785 |
Exchange | Taipei Exchange |
Fiscal Year | January - December |
Reporting Currency | TWD |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Yung-Shun Wen Ph.D. | Chief Executive Officer and Director |
Vivian Kang | Director of Finance |